Titration of β-blockers in heart failure: How to maximize benefit while minimizing adverse events

Postgraduate Medicine

Volumn 113, Issue 3, 2003, Pages 63-70

  Basile, Jan N ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; CARVEDILOL; METOPROLOL;

BRADYCARDIA; CHRONIC DISEASE; CONFERENCE PAPER; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FLUID RETENTION; HEART BLOCK; HEART FAILURE; HUMAN; HYPOTENSION; MAINTENANCE THERAPY; TITRIMETRY;

EID: 0037338386     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2003.03.1389     Document Type: Conference Paper

References (27)

1. Califf RM, O'Connor CM. β-Blocker therapy for heart failure: the evidence is in, now the work begins. (Editorial) JAMA 2000;283(10):1335-7
2. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. Heart Failure Society of America. Pharmacotherapy 2000;20(5):495-522
3. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334(21):1349-55
4. Waagstein F, Caidahl K, Wallentin I, et al. Long-term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80(3):551-63
5. Consensus recommendations for the management of chronic heart failure: on behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83(2A):1-38A
6. Hjalmarson Å, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283(10):1295-302
7. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353(9146):9-13
8. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344(22):1651-8
9. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiot 2001;38(4):932-8
10. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001-7
11. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94(11):2807-16
12. Deedwania PC, Giles TD, Ghali JK, et al. Safety and efficacy of treatment with metoprolol CR/XL in diabetic patients with heart failure. (Abstr) Circulation 2000;102(18 Suppl II):779
13. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol 1995;25(5):1154-61
14. Haber HL, Simek CL, Gimple LW, et al. Why do patients with congestive heart failure tolerate the initiation of β-blocker therapy? Circulation 1993;88(4 Pt 1):1610-9
15. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88(3):223-9
16. Toprol-XL package insert. Wilmington, Del: AstraZeneca Pharmaceuticals, April 2001
17. Coreg package insert. Philadelphia: SmithKline Beecham Pharmaceuticals, March 1999
18. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100(23):2312-8
19. Sanderson JE, Chan SK, Yip G, et al. β-Blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34(5):1522-8
20. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of β-adrenergic blockade in patients with chronic heart failure. (Editorial) Am J Cardiol 1997;79(6):794-8
21. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997;349(9049):375-80
22. Bright RA, Everitt DE. β-Blockers and depression: evidence against an association.]AMA 1992;267(13):1783-7
23. Dahlof C, Dimenas E, Kendall M, et al. Quality of life in cardiovascular diseases: emphasis on β-blocker treatment. Circulation 1991;84 (6 Suppl):V1108-18
24. Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of β-blockers. Arch Intern Med 1989;149(3):514-25
25. Jansen RW, Gurwitz JH. Controversies surrounding the use of β-blockers in older patients with cardiovascular disease. Drugs Aging 1994;4(3):175-83
26. Radack K, Deck C. β-Adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a metaanalysis of randomized controlled trials. Arch Intern Med 1991;151(9):1769-76
27. Tsuyuki RT, McAlister FA, Teo KK. β-Blockers for congestive heart failure: What is the current consensus? Drugs Aging 2000;16(1):-7